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Abstract
Purpose: To assess usefulness and tolerability of switching glaucoma patients to the fixed combination Travoprost
0.004%/Timolol 0.5% with polyquad (PQ-TTFC); to record effects on tear film break-up time (TF-BUT) and on
quality of life (OSDI).
Methods: Multicenter, observational cohort, 6 month study. 50 patients on concomitant Timolol 0.5% (twice a day)
and Dorzolamide (twice a day) or Timolol and Latanoptost (once a day) (BAK-preserved) were switched to PQ-TTFC
(evening dosage). IOP, TFBUT and AEs were recorded and all patients completed the OSDI questionnaire at
baseline and after 6 months. All analysis refers to right eye; left eye’s data are similar.
Results: Median age was 70 [63-73] years, women were 54.9% of the sample. IOP significantly decreased (from 18
[16-21] to 15 [12-17] mmHg) after substitution (p<0,001). At baseline 31.4% of patients presented an IOP
<18mmHg, the percentage increased to 80% of subjects at 6 months (p<0.001). TF-BUT improved of 2.7±1.9 sec
(from 7 [5-8] to 10 [9-11] sec, p<0.001). Only one patient discontinued the new therapy due to periocular skin
pigmentation. Quality of life improved from 28 (moderate) to 19 (mild) (p<0.001).
Conclusions: PQ-TTFC appeared useful in this selected population: patients who underwent a regimen
modification to PQ-TTFC obtained further reduction in IOP; improvement in ocular surface status with no
exposition to BAK toxicity; and reported a better quality of life perception. The low discontinuation’s rate at 6
months indicates a good tolerability profile.
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